Diverging from traditional target inhibition, proteasomal protein degradation approaches
have emerged as novel therapeutic modalities that embody distinct pharmacological profiles …

Current drug development strategies that target either enzymatic or receptor proteins for
which specific small molecule ligands can be designed for modulation, result in a large …

Small molecules continue to dominate drug discovery because of their ease of use, lower
cost of manufacturing, and access to intracellular targets. However, despite these …

Targeted protein degradation mediated by small molecule degraders represents an exciting
new therapeutic opportunity to eliminate disease-causing proteins. These molecules recruit …

Targeted protein degradation has exploded over the past several years due to preclinical
and early clinical therapeutic success of numerous compounds, and the emergence of new …

Targeted protein degradation (TPD) is a recent strategy, utilizing the cell's proteostasis
machinery to deplete specific proteins. This represents a paradigm shift in early drug …

Targeted protein degradation is a broad and expanding field aimed at the modulation of
protein homeostasis. A focus of this field has been directed toward molecules that hijack the …

The therapeutic modality of targeted protein degradation promises to overcome limitations of
traditional pharmacology. Small-molecule degraders recruit disease-causing proteins to E3 …

Targeted protein degradation refers to the use of small molecules to induce the selective
degradation of proteins. In its most common form, this degradation is achieved through …

Targeted protein degradation is becoming a weapon of choice against targets considered
heretofore “undruggable.” Whereas most small molecules inhibit a protein by blocking its …